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This Talk will cover… 
Drug Screening (in vitro, bioinformatics) 
Clinical trial 
HCV (epidemiology, genome, pathogenesis, treatment) 
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HCV Prevalence 
3 
Kazakhstan 
HCV in Kazakhstan (EHRN)        
20-50% in high risk groups 
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Mild Moderate Severe 
15%-30% 70%-85% 
Acute HCV Infection 
Recovery Chronic HCV Infection 
Cirrhosis  
Hepatocellular Carcinoma End-Stage Liver Disease 
Death 
HCV Pathogenesis 
15%-20% 
4% 
4% 
Protease inhibitors 
Boceprevir 
Telaprevir 
Simeprevir 
Sofosbuvir 
2011 2013 2014 
Ledipasvir 
Sofosbuvir 
Ombitasvir 
Paritaprevir 
Ritonavir 
Dasabuvir 
Treatment for HCV 
Polymerase inhibitors 
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PEGylated Interferon 
Ribavirin 
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Limitations of treatment 
PEGylated Interferon 
Ribavirin 
Long duration 
Adverse effects 
Affordability 
Resistance to treatment 
Subtype variation 
7 
HCV Genome 
+ve ssRNA 
(9.6 kb) 
Helicase  
Protease Helicase  
Drug Targets 
DNA 
Helicase 
UNWINDING 
Helicase Action 
Inhibitor Trimeric  
complex 
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Clinical trial 
Cell Culture models 
Enzyme assays 
Bioinformatics 
Drug Screening for HCV 
Drug Screening for HCV 
Huh8 cells 
HCV Replicon 
Huh7 cells 
HCV virion 
HCV NS3   
Helicase  
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Drug Screening for HCV 
Huh8 cells 
HCV Replicon 
Incubate cells  
with drug 
Quantify  
HCV RNA 
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Drug Screening for HCV 
Huh8 cells 
HCV Replicon 
Huh7 cells 
HCV virion 
HCV NS3 
Helicase  
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Drug Screening for HCV 
Huh7 cells 
HCV virion 
Infect cells with HCV 
Incubate cells with drug 
Quantify HCV RNA 
13 
Drug Screening for HCV 
Huh8 cells 
HCV Replicon 
Huh7 cells 
HCV virion 
HCV NS3 
Helicase  
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Drug Screening for HCV 
HCV NS3  
Helicase  
Purify viral helicase 
Measure activity  
With and without drug 
15 
16 
Bioinformatics 
Docking Analysis 
Drug-Target interactions  
Ligand Docking Energy (KJ/mol) 
FlexX Molegro 
  
Sparfloxacin 
  
          -20.5  
  
-86.6 
  
Ofloxacin 
  
-17.9 
  
-85.1 
  
Balofloxacin 
  
-17.3 
  
-81.0 
  
Pefloxacin 
  
-15.9 
  
-79 
  
Levofloxacin  
  
-15.8 
  
-75.6 
  
Lomefloxacin 
  
-15.6 
  
-75.2 
  
Ciprofloxacin 
  
-15.4  
  
-74.4 
  
Enrofloxacin 
  
  
-14.7 
  
-74.1 
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Drug-Target interactions  
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Summary 
HCV NS3 helicase inhibitors: 
 
  HCV replicon 
      HCV virion synthesis 
   HCV helicase 
  Computer modeling 
  Screening for novel inhibitors 
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